No significant association was observed for GPD1 (OR: 1.00, 95% CI: 0.74-1.36; p = 0.98).<h4>Conclusions</h4>Metformin may prevent colorectal cancer via the AMPKγ1 (PRKAG1) target based on genetic evidence, supporting the evaluation of metformin use in colorectal cancer prevention using randomised controlled trials. The gene discussed is PRKAG1; the disease is colorectal cancer.